#United States #Pleasanton #Atera #10x Genomics #Spatial Biology

10x Genomics Launches Atera for Cutting-Edge Spatial Biology

In a significant step for life sciences, 10x Genomics, Inc. has officially commenced global shipments of its latest innovation, Atera. This comes in response to the extraordinary early demand among researchers keen to harness the platform's unprecedented capabilities in spatial biology. The new instrument promises to provide a transformative edge in biological understanding, encouraging researchers to explore complex questions about human health and disease.

Launched in April 2026, Atera integrates advanced features such as whole transcriptome analysis and sub-cellular resolution with single-cell sensitivity. This powerful combination is set to eliminate historical trade-offs that have limited the scope and accessibility of spatial studies in the biological field. Not only does it cater to seasoned researchers who aim to scale existing spatial programs, but it also opens doors for those engaging with spatial biology for the first time, covering a range of fields including discovery research, translational studies, and biopharmaceutical applications.

Unprecedented Research Opportunities

As Atera enters the hands of researchers worldwide, its impact is poised to extend across various domains of inquiry. The breadth of research anticipated includes investigating major diseases such as oncology, neurodegenerative conditions, autoimmune disorders, and many others. Specifically, the platform is designed to facilitate foundational efforts in
cell and tissue atlasing, elucidating disease mechanisms, and examining therapeutic responses, as well as contributing significantly to biomarker discovery and the generation of expansive datasets for AI training.

Serge Saxonov, Co-founder and CEO of 10x Genomics, expressed his excitement by stating, "We built Atera with the ambition to fundamentally change how researchers measure and understand biology. The remarkable response since launch reinforces our conviction that Atera will do exactly that." This sentiment reflects the initial excitement and engagement observed among various research institutions, which indicates just how profoundly Atera may influence biological research methodologies.

Among the notable organizations leading the charge in utilizing Atera is the Allen Institute, renowned for its pioneering efforts in spatial biology. Researchers there are already engaging Atera to generate whole transcriptome spatial datasets from human tissues, which will significantly contribute to studies across immunology and neuroscience. Meanwhile, the Wellcome Sanger Institute anticipates that Atera will invigorate diverse projects while enhancing global initiatives such as the Human Cell Atlas.

Expanding Biopharma Applications

Atera's influence is not limited to academia; biopharmaceutical companies are equally invested in its capabilities. With nearly all of the world’s top 20 R&D-spending biopharma firms actively purchasing Atera systems or leveraging services from 10x’s service lab, Catalyst Research Services, the platform is anticipated to revolutionize drug discovery and development.

Researchers at the University of Texas MD Anderson Cancer Center are set to leverage Atera for translational cancer research. According to Dr. Linghua Wang, the tool will provide crucial insights into cellular responses to therapies, moving past mere descriptions to predictive capabilities regarding treatment efficiencies and resistance.

The Translational Genomics Research Institute (TGen) is preparing to integrate Atera into its broad spectrum of translational research applications, filling a significant gap in spatial profiling sensitivity and throughput. This collaboration promises benefits to the scientific community, highlighting Atera’s role in enabling high-quality data generation at scale, which is essential for advancing clinical applications.

Future Innovations

The potential of Atera is only beginning to unfold. Future enhancements are planned to further streamline the experimental workflow, combining biological information comprehensively and addressing a wider array of research inquiries. Some anticipated capabilities include:

• - Slide Prep Automation: Streamlining manual processes directly within the instrument to improve ease of use.
• - RNA-Protein Multiomics: Offering the ability to measure RNA and protein together at the same-cell level, deepening insights into biological functions.
• - Mutation Detection In Situ: Introducing targeted mutation analysis in conjunction with gene expression within the same cellular context.

Michael Schnall-Levin, Chief Technology and Strategy Officer at 10x Genomics, stated, "The biggest advances in science come from rethinking limitations and evolving the technology to meet new biological questions." This innovative mindset is foundational to the development of Atera.

In conclusion, Atera represents not just a product launch but the beginning of a new era in biological research. As it offers robust capabilities for elucidating the complexities of life sciences, researchers and organizations alike can look forward to new levels of discovery and understanding in their respective fields. For those eager to learn more about Atera and its transformative potential in research, further information can be found at 10x Genomics.

• ---

_About 10x Genomics:_ 10x Genomics is dedicated to advancing human health through innovative life science technology aimed at unlocking the complexities of biology. With strong product offerings tailored for researchers in academia and biopharma, the company remains at the forefront of breakthroughs aimed at transforming the knowledge landscape in health and disease.